BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16320335)

  • 21. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice.
    Harrington JT
    J Rheumatol; 2009 May; 36(5):925-9. PubMed ID: 19369466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
    Mäkinen H; Kautiainen H; Hannonen P; Sokka T
    J Rheumatol; 2008 Aug; 35(8):1522-7. PubMed ID: 18484699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases?
    Wolfe F; Michaud K; Simon T
    J Rheumatol; 2006 Oct; 33(10):1952-6. PubMed ID: 16960927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment.
    Veehof MM; ten Klooster PM; Taal E; van Riel PL; van de Laar MA
    Ann Rheum Dis; 2008 Jun; 67(6):789-93. PubMed ID: 17974597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice.
    Choy EH; Khoshaba B; Cooper D; MacGregor A; Scott DL
    Arthritis Rheum; 2008 Feb; 59(2):192-9. PubMed ID: 18240256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN).
    Kiely P; Walsh D; Williams R; Young A;
    Rheumatology (Oxford); 2011 May; 50(5):926-31. PubMed ID: 21169343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
    Soubrier M; Zerkak D; Gossec L; Ayral X; Roux C; Dougados M
    J Rheumatol; 2006 Jul; 33(7):1243-6. PubMed ID: 16622906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring the epidemiology of distress: the rheumatology distress index.
    Wolfe F; Skevington SM
    J Rheumatol; 2000 Aug; 27(8):2000-9. PubMed ID: 10955344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Kapral T; Dernoschnig F; Machold KP; Stamm T; Schoels M; Smolen JS; Aletaha D
    Arthritis Res Ther; 2007; 9(4):R72. PubMed ID: 17662115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.